Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AGNC Investment Corp AGNCN


Primary Symbol: AGNC

AGNC Investment Corp. is an internally managed real estate investment trust (REIT). The Company provides private capital to the United States housing market, enhancing liquidity in the residential real estate mortgage markets and, in turn, facilitating home ownership in the United States. The Company invest primarily in Agency residential mortgage-backed securities (Agency RMBS) on a leveraged basis. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a United States Government-sponsored enterprise, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac, and together with Fannie Mae, the GSEs), or by a United States Government agency, such as the Government National Mortgage Association (Ginnie Mae). It may also invest in other assets related to the housing, mortgage or real estate markets.


NDAQ:AGNC - Post by User

Post by stockpatrolon Nov 02, 2022 6:05pm
145 Views
Post# 35068060

AGN.c CEO Chris Moreau discussing Phase 2 of the Yale clinic

AGN.c CEO Chris Moreau discussing Phase 2 of the Yale clinic
AGN.c CEO Chris Moreau discussing Phase 2 of the Yale clinical trial for DMT. 
 
https://www.youtube.com/watch?app=desktop&v=7iXLVqZleKo&ab_channel=RadiusResearch
 
AGN and Yale retain the intellectual property from the trials, AGN is supplying their new form of DMT. The additional data from these trials will assist AGN's ongoing DMT trials for treating strokes.
<< Previous
Bullboard Posts
Next >>